POLISCOPE
Back to feed
FEDERALhearing transcript

Congressional Hearing on the Pet Medication Industry

Original title: THE PET MEDICATIONS INDUSTRY: ISSUES AND PERSPECTIVES

January 1, 2016

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing explored regulatory and market dynamics affecting how pet owners access and purchase medications for their animals, which impacts the cost and availability of veterinary care.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pet owners

The regulatory environment for pet medications directly influences the cost and accessibility of treatments for their animals.

Veterinarians

Veterinarians are involved in the prescribing and dispensing of medications, which is subject to industry regulations and market practices.

Pet medication manufacturers

Manufacturers are subject to federal trade and health regulations discussed during the hearing.

What changed

Last recorded activity January 1, 2016.

What's next

Next step not available in the current record.

Summary

This document is a transcript record of a 2016 House hearing regarding the pet medication industry. The hearing featured testimony from the Federal Trade Commission, veterinary associations, and industry representatives to discuss market issues and perspectives.

Key Facts

  • The hearing was held on April 29, 2016, by the Subcommittee on Commerce, Manufacturing, and Trade.
  • The session focused on the 'Pet Medications Industry: Issues and Perspectives'.
  • Testimony was provided by representatives from the Federal Trade Commission, True Science, LLC, and the American Veterinary Medical Association.
  • The record includes submitted statements from the Animal Health Institute and the Consumers Union.
  • The hearing was conducted during the 114th Congress, Second Session.

Frequently Asked Questions

What was the purpose of this hearing?
The hearing was held to examine the current state of the pet medication industry, including market issues and perspectives from regulators, veterinarians, and industry stakeholders.
Who testified at the hearing?
Witnesses included Tara Koslov from the Federal Trade Commission, Nathan Smith from True Science, LLC, and Dr. John de Jong from the American Veterinary Medical Association.

Why It Matters

The hearing explored regulatory and market dynamics affecting how pet owners access and purchase medications for their animals, which impacts the cost and availability of veterinary care.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

cross reference90% confidence

Historical Regulatory Review

The hearing serves as a snapshot of the 2016 regulatory landscape regarding the intersection of veterinary practice and the retail pet medication market.

Connected Entities

personTara KoslovDeputy Director, Office of Policy Planning, Federal Trade CommissionMap →
personJanice D. SchakowskyRanking Member of the SubcommitteeMap →
personMichael C. BurgessChairman of the Subcommittee on Commerce, Manufacturing, and TradeMap →
organizationAmerican Veterinary Medical AssociationProfessional association providing testimonyMap →
personNathan SmithVice President of Strategy and International, True Science, LLCMap →
personJohn de JongChair, Board of Directors, American Veterinary Medical AssociationMap →
organizationFederal Trade CommissionFederal regulatory body providing testimonyMap →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance40
    How much this matters to a regular citizen
  • Controversy20
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz10
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record